AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Amgen (AMGN) and AstraZeneca (AZN) reported positive phase III study results for their lung cancer drug combination, Imdelltra and Imfinzi, showing improved overall and progression-free survival. The study, DeLLphi-305, evaluated the combination against Imfinzi alone in extensive-stage small-cell lung cancer (SCLC) patients. Both companies highlighted the potential market opportunity, with SCLC accounting for 15% of lung cancers and an estimated 195,000 global cases in 2026. Imdelltra's sales re
How this was made
The 30-second read
Why it matters
The trial meets its primary overall survival endpoint, suggesting a meaningful clinical benefit that could expand both drugs' markets.
Market read
First‑time positive Phase III data for a major oncology combo, likely to move both stocks and the broader cancer‑therapy sector.
What to watch
Competitive landscape with Jazz/Roche combo and potential reimbursement challenges could limit upside.
Background
The DeLLphi‑305 trial compares the Imfinzi‑Imdelltra combo against Imfinzi alone in first‑line maintenance for extensive‑stage SCLC.
Ticker impact
Amgen announced positive Phase III results for its lung cancer drug Imdelltra in combination with AstraZeneca's Imfinzi, achieving overall survival and PFS endpoints.
upside pressure on AMGN as investors price in larger addressable market.
First‑time disclosure of pivotal trial data with no safety concerns and a clear efficacy signal.
AstraZeneca's Imfinzi showed a survival benefit when combined with Amgen's Imdelltra in the DeLLphi‑305 study, meeting primary and key secondary endpoints.
moderate upside for AZN as the combo may expand Imfinzi's usage.
New trial data directly supports broader indication, likely to be reflected in near‑term pricing.
Market effects
Boosts outlook for biotech firms developing bispecific T‑cell engagers and immunotherapy combos in lung cancer.
Positive for US and European biotech markets, with potential spill‑over to oncology‑focused ETFs.
Adds to global SCLC treatment pipeline, may influence investor sentiment worldwide.
Counterpoint
If the combination fails to secure regulatory approval or faces pricing pressure, the initial hype could reverse.
Key entities
- CompanyAmgen
Biopharma developing Imdelltra (tarlatamab).
- CompanyAstraZeneca
Pharma company behind Imfinzi (durvalumab).
